GB8513754D0
(en)
*
|
1985-05-31 |
1985-07-03 |
Jones T R |
Anti-cancer quinazoline derivatives
|
GB8625019D0
(en)
*
|
1986-10-18 |
1986-11-19 |
Wellcome Found |
Compounds
|
GB8707053D0
(en)
*
|
1987-03-25 |
1987-04-29 |
Ici Plc |
Anti-tumour agents
|
US4857530A
(en)
*
|
1987-11-03 |
1989-08-15 |
Warner-Lambert Company |
Substituted quinazolinones as anticancer agents
|
GB8727737D0
(en)
*
|
1987-11-26 |
1987-12-31 |
Ici Plc |
Antitumour agents
|
US4940713A
(en)
*
|
1988-04-15 |
1990-07-10 |
Burroughs Wellcome Co. |
Substituted glutamic acids
|
US5019577A
(en)
*
|
1988-04-15 |
1991-05-28 |
Burroughs Welcome Co. |
Novel compounds and use
|
GB8809978D0
(en)
*
|
1988-04-27 |
1988-06-02 |
Ici Plc |
Anti-tumour agents
|
EP0365763A1
(en)
*
|
1988-09-30 |
1990-05-02 |
Agouron Pharmaceuticals, Inc. |
Antiproliferative cyclic compounds
|
US5252573A
(en)
*
|
1988-12-15 |
1993-10-12 |
Imperial Chemical Industries Plc |
Anti-tumor agents
|
GB8829296D0
(en)
*
|
1988-12-15 |
1989-01-25 |
Ici Plc |
Anti-tumour compounds
|
US5286726A
(en)
*
|
1990-04-12 |
1994-02-15 |
The Regents Of The University Of Michigan |
Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases
|
ZA913730B
(en)
*
|
1990-05-30 |
1992-02-26 |
Ici Plc |
Anti-tumor compounds
|
GB9013615D0
(en)
*
|
1990-06-19 |
1990-08-08 |
Wellcome Found |
Pharmaceutical compounds
|
US5290780A
(en)
*
|
1991-01-30 |
1994-03-01 |
American Cyanamid Co. |
Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
|
GB9105771D0
(en)
*
|
1991-03-19 |
1991-05-01 |
Cancer Res Inst Royal |
Anti-cancer compounds
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
DE69216509T2
(de)
*
|
1991-08-12 |
1997-05-28 |
Takeda Chemical Industries Ltd |
Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel
|
US5145854A
(en)
*
|
1991-11-27 |
1992-09-08 |
Nair Madhavan G |
1-formyl-5,8,10-trideazafolates
|
GB9205320D0
(en)
*
|
1992-03-11 |
1992-04-22 |
Ici Plc |
Anti-tumour compounds
|
GB9205907D0
(en)
*
|
1992-03-18 |
1992-04-29 |
Cancer Res Inst Royal |
Anti-cancer compounds
|
ES2049659B1
(es)
*
|
1992-10-08 |
1994-10-16 |
Ici Plc |
Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
|
GB9223352D0
(en)
*
|
1992-11-06 |
1992-12-23 |
Ici Plc |
Tricyclic compounds
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US7910624B1
(en)
|
1995-03-03 |
2011-03-22 |
The Trustees Of Boston University |
Compositions for the treatment of blood disorders
|
AU696167B2
(en)
*
|
1993-10-29 |
1998-09-03 |
Trustees Of Boston University |
Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
|
US6011000A
(en)
*
|
1995-03-03 |
2000-01-04 |
Perrine; Susan P. |
Compositions for the treatment of blood disorders
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US5593999A
(en)
*
|
1995-06-07 |
1997-01-14 |
Nair; Madhavan G. |
Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
|
US6420427B1
(en)
*
|
1997-10-09 |
2002-07-16 |
Ono Pharmaceutical Co., Ltd. |
Aminobutyric acid derivatives
|
US5912251A
(en)
*
|
1998-01-17 |
1999-06-15 |
Nair; Madhavan G. |
Metabolically inert anti-inflammatory and anti-tumor antifolates
|
WO1999040883A2
(en)
*
|
1998-02-11 |
1999-08-19 |
Faller Douglas V |
Compositions and methods for the treatment of cystic fibrosis
|
GB9904275D0
(en)
|
1999-02-24 |
1999-04-21 |
Cancer Res Campaign Tech |
Anti-cancer compounds
|
US7230000B1
(en)
*
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US7671200B2
(en)
*
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US6545004B1
(en)
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US6143776A
(en)
*
|
2000-02-02 |
2000-11-07 |
Sunesis Pharmaceuticals, Inc. |
Tosylproline analogs as thymidylate synthase inhibitors
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
KR20100043294A
(ko)
|
2001-08-31 |
2010-04-28 |
비티지 인터내셔널 리미티드 |
항암제로서 사용되는 시클로펜타[g]퀴나졸린 화합물
|
DK1420809T3
(da)
|
2001-08-31 |
2011-12-19 |
Btg Int Ltd |
Anvendelse af cyclopenta[G]quinazolinderivater til behandling af cancer
|
US6753428B2
(en)
*
|
2001-11-20 |
2004-06-22 |
Cytokinetics, Inc. |
Process for the racemization of chiral quinazolinones
|
CA2475879A1
(en)
*
|
2002-02-15 |
2003-08-28 |
Cytokinetics, Inc. |
Synthesis of quinazolinones
|
PL401637A1
(pl)
|
2002-03-13 |
2013-05-27 |
Array Biopharma Inc. |
N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
|
AU2003223786A1
(en)
*
|
2002-05-09 |
2003-11-11 |
Cytokinetics, Inc. |
Compounds, methods and compositions
|
WO2003097053A1
(en)
*
|
2002-05-09 |
2003-11-27 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
JP2005536475A
(ja)
*
|
2002-05-23 |
2005-12-02 |
サイトキネティクス・インコーポレーテッド |
化合物、組成物、および方法
|
WO2003106426A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
US7211580B2
(en)
*
|
2002-07-23 |
2007-05-01 |
Cytokinetics, Incorporated |
Compounds, compositions, and methods
|
US20040048853A1
(en)
*
|
2002-08-21 |
2004-03-11 |
Gustave Bergnes |
Compounds, compositions, and methods
|
PA8580301A1
(es)
|
2002-08-28 |
2005-05-24 |
Pfizer Prod Inc |
Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
|
EP1558083A4
(en)
*
|
2002-09-30 |
2008-04-16 |
Cytokinetics Inc |
COMPOUNDS, COMPOSITIONS AND METHODS
|
AU2003285614B2
(en)
|
2002-12-20 |
2009-05-14 |
Pfizer Products, Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
US20050197327A1
(en)
*
|
2003-11-03 |
2005-09-08 |
Gustave Bergnes |
Compounds, compositions, and methods
|
JP2007510660A
(ja)
*
|
2003-11-07 |
2007-04-26 |
サイトキネティクス・インコーポレーテッド |
化合物、組成物及び方法
|
WO2005051302A2
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Bicyclic inhibitors of mek and methods of use thereof
|
EP1692112A4
(en)
*
|
2003-12-08 |
2008-09-24 |
Cytokinetics Inc |
COMPOUNDS, COMPOSITIONS, AND METHODS
|
BRPI0511512A
(pt)
|
2004-05-27 |
2007-12-26 |
Pfizer Prod Inc |
derivados pirrolpirimidina úteis no tratamento do cáncer
|
JP2008512490A
(ja)
|
2004-09-08 |
2008-04-24 |
チェルシー・セラピューティクス,インコーポレイテッド |
異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
CA2604357C
(en)
|
2005-04-26 |
2012-01-17 |
Pfizer Inc. |
P-cadherin antibodies
|
KR20080019236A
(ko)
|
2005-05-18 |
2008-03-03 |
어레이 바이오파마 인크. |
Mek의 헤테로시클릭 억제제 및 그의 사용 방법
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
UY29783A1
(es)
|
2005-09-07 |
2007-04-30 |
Pfizer |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
ATE483463T1
(de)
|
2006-04-18 |
2010-10-15 |
Ardea Biosciences Inc |
Pyridonsulfonamide und pyridonsulfamide als mek- hemmer
|
RS20080525A
(en)
|
2006-05-09 |
2009-09-08 |
Pfizer Products Inc., |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
CA2674698A1
(en)
|
2007-01-19 |
2008-07-24 |
Chelsea Therapeutics, Inc. |
New classical antifolates
|
WO2010105112A1
(en)
*
|
2009-03-11 |
2010-09-16 |
Hemaquest Pharmaceuticals, Inc. |
Detection of short-chain fatty acids in biological samples
|
CA2756566A1
(en)
|
2009-03-27 |
2010-09-30 |
Ardea Biosciences, Inc. |
Dihydropyridin sulfonamides as mek inhibitors
|
HRP20171415T4
(hr)
|
2009-06-25 |
2023-03-03 |
Alkermes Pharma Ireland Limited |
Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
US20110086869A1
(en)
|
2009-09-24 |
2011-04-14 |
The Trustees Of Boston University |
Methods for treating viral disorders
|
KR20120103604A
(ko)
|
2009-11-06 |
2012-09-19 |
첼시 쎄라퓨틱스, 인코포레이티드 |
효소 저해성 화합물
|
WO2011068403A2
(en)
|
2009-12-02 |
2011-06-09 |
Ultimorphix Technologies B.V. |
Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts
|
US8618068B2
(en)
|
2009-12-08 |
2013-12-31 |
Trustees Of Boston University |
Methods and low dose regimens for treating red blood cell disorders
|
CA2798172C
(en)
*
|
2010-01-07 |
2017-11-21 |
Alkermes Pharma Ireland Limited |
Quaternary ammonium salt prodrugs
|
ES2753748T3
(es)
|
2010-02-12 |
2020-04-14 |
Pfizer |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
|
WO2011113013A2
(en)
|
2010-03-11 |
2011-09-15 |
Hemaquest Pharmaceuticals, Inc. |
Methods and compositions for treating viral or virally-induced conditions
|
NZ604423A
(en)
|
2010-06-24 |
2015-01-30 |
Alkermes Pharma Ireland Ltd |
Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
|
BR112013005223A2
(pt)
|
2010-09-03 |
2016-05-03 |
Bayer Ip Gmbh |
"pirimidinonas e dihidropirimidinonas fusionadas substituídas."
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
WO2012078708A1
(en)
|
2010-12-07 |
2012-06-14 |
Chelsea Therapeutics, Inc. |
Combination comprising methotrexate and an antifolate compound
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
CN103561746B
(zh)
|
2011-03-18 |
2018-05-29 |
奥克梅斯制药爱尔兰有限公司 |
包含脱水山梨糖醇酯的药物组合物
|
CA2847540C
(en)
|
2011-09-22 |
2016-05-17 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
CN102424679B
(zh)
*
|
2011-11-15 |
2014-07-30 |
扬子江药业集团有限公司 |
一种雷替曲塞的制备方法
|
ES2764383T3
(es)
|
2012-03-19 |
2020-06-03 |
Alkermes Pharma Ireland Ltd |
Composiciones farmacéuticas que comprenden ésteres de glicerol
|
ES2950418T3
(es)
|
2012-03-19 |
2023-10-09 |
Alkermes Pharma Ireland Ltd |
Composiciones farmacéuticas que comprenden alcohol bencílico
|
EP2827868B8
(en)
|
2012-03-19 |
2019-12-18 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising fatty acid esters
|
NZ631345A
(en)
|
2012-09-19 |
2017-06-30 |
Alkermes Pharma Ireland Ltd |
Pharmaceutical compositions having improved storage stability
|
WO2015051302A1
(en)
|
2013-10-04 |
2015-04-09 |
Aptose Biosciences Inc. |
Compositions and methods for treating cancers
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
JP6524110B2
(ja)
|
2014-03-20 |
2019-06-05 |
アルカームス ファーマ アイルランド リミテッド |
注射速度が増大したアリピプラゾール調合物
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
MX2016014143A
(es)
|
2014-04-30 |
2017-02-15 |
Pfizer |
Derivados de diheterociclo enlazado a cicloalquilo.
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
ES2718175T3
(es)
*
|
2014-12-02 |
2019-06-28 |
Lilly Co Eli |
Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
CN104447724B
(zh)
*
|
2014-12-31 |
2017-11-10 |
四川峨嵋山药业有限公司 |
一种雷替曲塞的精制方法
|
EA201890161A1
(ru)
|
2015-06-29 |
2018-06-29 |
Верастэм, Инк. |
Терапевтические композиции, комбинации и способы применения
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
HUE052893T2
(hu)
|
2016-01-13 |
2021-05-28 |
Acerta Pharma Bv |
Antifolát és BTK-gátló terápiás kombinációi
|
CN106957311B
(zh)
*
|
2016-12-29 |
2020-03-31 |
南京正大天晴制药有限公司 |
雷替曲塞的溶剂化物及其制备方法
|
CN106957312B
(zh)
*
|
2016-12-29 |
2019-11-01 |
南京正大天晴制药有限公司 |
雷替曲塞水合物晶型及其制备方法
|
AU2019230014A1
(en)
|
2018-03-05 |
2020-09-17 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
CN109734698B
(zh)
*
|
2019-01-25 |
2020-07-17 |
宏冠生物药业有限公司 |
一种雷替曲塞关键中间体的合成工艺
|
SG11202113215UA
(en)
|
2019-05-31 |
2021-12-30 |
Viracta Subsidiary Inc |
Methods of treating virally associated cancers with histone deacetylase inhibitors
|
PE20220808A1
(es)
|
2019-06-18 |
2022-05-20 |
Pfizer |
Derivados de benzisoxazol sulfonamida
|
US20220251075A1
(en)
|
2019-06-19 |
2022-08-11 |
Pfizer Inc. |
Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives
|